Analysis of tumor microenvironment changes after neoadjuvant chemotherapy with or without bevacizumab in advanced ovarian cancer (GEICO-89T/MINOVA study).
Beatriz TaviraTeresa IscarLuis Manso SanchezAna Santaballa BertranMarta Gil-MartinYolanda García GarcíaMargarita Romeo MarinMaria IglesiasAna de Juan FerréMaria-Pilar Barretina GinestaAránzazu Manzano FernándezLydia GabaMaría Jesús RubioCarlos E De AndreaAntonio Gonzáles MartinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
The addition of bevacizumab to NACT did not have an impact on PFS in the GEICO 1205 study. However, at cellular level, changes in CD4+, CD8+lymphocyte populations, and CD8+/CD4+FOXP3 ratio have been detected only at the stromal site. Based on our results, we hypothesize about the existence of mechanisms of resistance that could prevent the trafficking of T effector cells into the epithelial component of the tumor as a potential explanation for the lack of efficacy of ICI in the first line of advanced EOC.